EA202193351A1 - Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы - Google Patents

Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы

Info

Publication number
EA202193351A1
EA202193351A1 EA202193351A EA202193351A EA202193351A1 EA 202193351 A1 EA202193351 A1 EA 202193351A1 EA 202193351 A EA202193351 A EA 202193351A EA 202193351 A EA202193351 A EA 202193351A EA 202193351 A1 EA202193351 A1 EA 202193351A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binder
single antibody
antigen
binding portion
specific
Prior art date
Application number
EA202193351A
Other languages
English (en)
Inventor
Цинхао Лю
Вэньлай Чжоу
Хайянь Ян
Хунлин Ван
Original Assignee
Джакобио Фармасьютикалс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джакобио Фармасьютикалс Ко., Лтд. filed Critical Джакобио Фармасьютикалс Ко., Лтд.
Publication of EA202193351A1 publication Critical patent/EA202193351A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Связывающая молекула, специфическая в отношении CD73, и применение связывающей молекулы. В частности, обеспечиваются отдельное антитело, связывающее CD73 и ингибирующее активность CD73, или антигенсвязывающая часть отдельного антитела, и применение отдельного антитела или его антигенсвязывающей части в лечении заболеваний; также обеспечиваются молекула нуклеиновой кислоты, кодирующая отдельное антитело или его антигенсвязывающую часть, вектор экспрессии для экспрессии отдельного антитела или его антигенсвязывающей части, клетка-хозяин и способ получения.
EA202193351A 2019-06-06 2020-06-05 Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы EA202193351A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019090366 2019-06-06
PCT/CN2020/094489 WO2020244606A1 (zh) 2019-06-06 2020-06-05 对cd73具有特异性的结合分子及其用途

Publications (1)

Publication Number Publication Date
EA202193351A1 true EA202193351A1 (ru) 2022-03-21

Family

ID=73653110

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193351A EA202193351A1 (ru) 2019-06-06 2020-06-05 Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы

Country Status (12)

Country Link
US (2) US11174319B2 (ru)
EP (1) EP3981790A4 (ru)
JP (1) JP2022535840A (ru)
KR (1) KR20220016974A (ru)
CN (1) CN113906051A (ru)
AU (1) AU2020289179B2 (ru)
BR (1) BR112021024553A2 (ru)
CA (1) CA3142640A1 (ru)
EA (1) EA202193351A1 (ru)
MX (1) MX2021014952A (ru)
TW (1) TWI790445B (ru)
WO (1) WO2020244606A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294436A (en) 2020-01-03 2022-09-01 Incyte Corp Anti-cd73 antibodies and their uses
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
NZ728981A (en) * 2014-08-07 2024-03-22 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
RU2746804C2 (ru) * 2014-10-10 2021-04-21 Иннейт Фарма Блокада cd73
EA035766B1 (ru) * 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Антитело к cd73 и его применения
US11130817B2 (en) * 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CA3007646A1 (en) * 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
CN112279918A (zh) * 2017-01-24 2021-01-29 天境生物科技(上海)有限公司 Cd73抗体及其用途
EP3606962A4 (en) * 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. TREATMENT METHODS FOR HIGH CD73 TUMORS
CA3066774A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof

Also Published As

Publication number Publication date
US11174319B2 (en) 2021-11-16
CN113906051A (zh) 2022-01-07
KR20220016974A (ko) 2022-02-10
JP2022535840A (ja) 2022-08-10
US20210253730A1 (en) 2021-08-19
BR112021024553A2 (pt) 2022-05-24
EP3981790A1 (en) 2022-04-13
TWI790445B (zh) 2023-01-21
MX2021014952A (es) 2022-04-06
CA3142640A1 (en) 2020-12-10
EP3981790A4 (en) 2023-10-11
AU2020289179A1 (en) 2021-11-18
TW202112814A (zh) 2021-04-01
WO2020244606A1 (zh) 2020-12-10
AU2020289179B2 (en) 2024-05-02
US20220064322A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
EA202193351A1 (ru) Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2020004578A (es) Composiciones de casz y metodos de uso.
ZA202100676B (en) Anti-tigit antibody and uses thereof
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
CL2016002116A1 (es) Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13).
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
EA201890169A1 (ru) Тау-связывающие антитела
NO20083053L (no) Humane monoklonale antistoffer mot O8E
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201792522A1 (ru) Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
EA201892774A1 (ru) Антитела
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
EA201890172A1 (ru) Тау-связывающие антитела
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
EA201690503A1 (ru) Антитела
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
EA201900443A1 (ru) Антитело к pd-l1 и его применение